Ambagon Therapeutics
Eindhoven, US · Founded 2020 · Delaware corporation · 15 employees on LinkedIn · 7 known investors
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
Founders & leadership
Ambagon Therapeutics was founded in 2020 by Christian Ottmann.
CO
Christian OttmannFounder
JS
Josh SeidenfeldExecutive
MA
Michelle ArkinNamed on SEC filing
NP
Nancy PryerNamed on SEC filing
MC
Margarita ChavezNamed on SEC filing
BM
Bryan MillerNamed on SEC filing
AR
Adam RosenbergNamed on SEC filing
SC
Scott ClarkeNamed on SEC filing
Board
MM
Melissa McCrackenBoard directorPartner at Nextech Invest
PD
JN
RB
Investors · 7
Reported raises · per SEC filings
Form D private placements$55.4M disclosed across 3 rounds · 2021–2025
▶$5MraisedFeb 2025 · 4 investors · BiotechnologyRule 506(b)
▶$5MraisedFeb 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Melissa McCrackenDirector
- Josh SeidenfeldExecutive Officer
- Christian OttmannExecutive Officer
- Offering amount
- $12M
- Amount sold
- $5M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$45MraisedJun 2022 · 9 investors · BiotechnologyRule 506(b)
▶$45MraisedJun 2022 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Josh SeidenfeldExecutive Officer
- Michelle ArkinDirector
- Peter DudekDirector
- Roel BulthuisDirector
- Janwillem NaesensDirector
- Margarita ChavezDirector
- Nancy PryerExecutive Officer
- Christian OttmannExecutive Officer
- Adam RosenbergDirector
- Melissa McCrackenDirector
- Bryan MillerExecutive Officer
- Scott ClarkeExecutive Officer, Director
- Offering amount
- $85M
- Amount sold
- $45M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$5.4MraisedDec 2021 · 8 investors · BiotechnologyRule 506(b)
▶$5.4MraisedDec 2021 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michelle ArkinDirector
- Nancy PryerExecutive Officer
- Christian OttmannExecutive Officer
- Margarita ChavezDirector
- Peter DudekDirector
- Janwillem NaesensDirector
- Bryan MillerExecutive Officer
- Roel BulthuisDirector
- Adam RosenbergDirector
- Josh SeidenfeldExecutive Officer
- Scott ClarkeExecutive Officer, Director
- Offering amount
- $5.4M
- Amount sold
- $5.4M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Ambagon Therapeutics do?
- Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
- Who founded Ambagon Therapeutics?
- Ambagon Therapeutics was founded by Christian Ottmann in 2020.
- Who are Ambagon Therapeutics's investors?
- Ambagon Therapeutics's investors include Droia Ventures, Mission Biocapital, MRL Ventures Fund, Nextech Invest, Inkef, RA Capital, Syncona.
- How much funding has Ambagon Therapeutics raised?
- Ambagon Therapeutics has disclosed $55.4M raised across 3 rounds.
- Where is Ambagon Therapeutics headquartered?
- Ambagon Therapeutics is headquartered in Eindhoven, US.